Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ELCC 2019 | Second-generation ALK inhibitors in ALK-positive NSCLC

Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, talks about the survival benefits brought by second-generation ALK inhibitors in patients with ALK-positive non-small cell lung cancer (NSCLC). This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.